Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genvoya in Naïve HIV-1 Patients With Severe Immunosuppression
NCT03693508Phase 4Completed
- Sponsor
- Fundación SEIMC-GeSIDA
- Start
- Apr 2018
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Fundación SEIMC-GeSIDA. Primary endpoint: Percentage of patients with undetectable plasma viral load at 48 weeks. Started Apr 2018; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03693508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03693508.